Intraoperative Bleeding. Complications of procedures, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group 1 (Tranexamic Acid (TXA) Group):Patients in this group will receive prophylactic tranexamic acid at a dose of 10 mg/kg administered intravenously 10–15 minutes befor
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age 18 to 60 years Patients who are candidates for femoral fracture surgery (femoral neck, pretrochanteric, subtrochanteric) or primary hip arthroplasty Informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Coagulopathy (µL/150000 Plt , s 60 aPTT >) Severe renal failure (ml/min GFR < 30) History of allergy to Tranexamic Acid or vitamin K Taking anticoagulants (such as warfarin) or Co-Q10 Patient with antiphospholipid syndrome Patient's lack of informed consent to enter the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total perioperative blood loss is considered a primary indicator of the effectiveness of prophylactic interventions in controlling bleeding during femoral surgery. Timepoint: From the start of surgery until postoperative day 5. Method of measurement: Total blood loss will be calculated using the Mercuriali formula, which estimates blood loss based on changes in hemoglobin levels between preoperative values and postoperative day 5, adjusted for transfused blood volume and estimated patient blood volume. Intraoperative blood loss will additionally be recorded using suction canister volumes and weighted surgical sponges.;Blood transfusion requirement is considered the second primary outcome and reflects the clinical significance of bleeding and the effectiveness of patient blood management strategies. Timepoint: From the start of surgery until postoperative day 5 or hospital discharge, whichever occurs first. Method of measurement: Transfusion requirement will be recorded as the number of packed red blood cell (PRBC) units administered. Transfusion decisions will follow institutional protocols based on hemoglobin levels, clinical symptoms, and treating physician judgment. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNafiseh Faghani Makrani
Mazandaran University of Medical Sciences
Outcome results
None listed